[go: up one dir, main page]

MX2022010920A - Pld para uso en combinación con el tratamiento de coronavirus. - Google Patents

Pld para uso en combinación con el tratamiento de coronavirus.

Info

Publication number
MX2022010920A
MX2022010920A MX2022010920A MX2022010920A MX2022010920A MX 2022010920 A MX2022010920 A MX 2022010920A MX 2022010920 A MX2022010920 A MX 2022010920A MX 2022010920 A MX2022010920 A MX 2022010920A MX 2022010920 A MX2022010920 A MX 2022010920A
Authority
MX
Mexico
Prior art keywords
coronavirus
pld
treatment
combination
cov
Prior art date
Application number
MX2022010920A
Other languages
English (en)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Muñoz Salvador Fudio
Nuria Izquierdo-Useros
Júlia Vergara-Alert
Sousa-Faro José Maria Fernández
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2022010920A publication Critical patent/MX2022010920A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El uso de PLD con uno o más agentes antivirales contra CoV adicionales en el tratamiento de la infección por coronavirus (CoV).
MX2022010920A 2020-03-02 2021-03-02 Pld para uso en combinación con el tratamiento de coronavirus. MX2022010920A (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382821 2020-09-17
PCT/EP2021/055131 WO2021175823A1 (en) 2020-03-02 2021-03-02 Pld for use in combination in the treatment of coronavirus

Publications (1)

Publication Number Publication Date
MX2022010920A true MX2022010920A (es) 2022-11-30

Family

ID=74758810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010920A MX2022010920A (es) 2020-03-02 2021-03-02 Pld para uso en combinación con el tratamiento de coronavirus.

Country Status (13)

Country Link
US (1) US20230158103A1 (es)
EP (1) EP4114434A1 (es)
JP (1) JP2023517194A (es)
KR (1) KR20220150348A (es)
CN (1) CN115243703A (es)
AU (1) AU2021231521A1 (es)
BR (1) BR112022016653A2 (es)
CA (1) CA3169528A1 (es)
CO (1) CO2022014044A2 (es)
IL (1) IL296067A (es)
MX (1) MX2022010920A (es)
PE (1) PE20230302A1 (es)
WO (1) WO2021175823A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022092299A1 (ja) * 2020-10-30 2022-05-05 ｉ－ＤＲＴｓ株式会社 Ｃｏｖｉｄ－１９治療剤
CN114796177B (zh) * 2022-06-27 2022-09-30 广州国家实验室 抗冠状病毒药物和应用
CN117618452B (zh) * 2022-08-29 2024-08-23 山东如至生物医药科技有限公司 一种药物组合物及其制备方法和其在抗病毒方面的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
UY39108A (es) * 2020-03-02 2021-09-30 Pharma Mar Sa Compuestos para su uso en el tratamiento de la infección por coronavirus
KR20220151643A (ko) * 2020-03-02 2022-11-15 파르마 마르, 에스.에이. 바이러스 감염에 사용하기 위한 화합물

Also Published As

Publication number Publication date
CA3169528A1 (en) 2021-09-10
PE20230302A1 (es) 2023-02-13
KR20220150348A (ko) 2022-11-10
BR112022016653A2 (pt) 2022-10-11
US20230158103A1 (en) 2023-05-25
CN115243703A (zh) 2022-10-25
AU2021231521A1 (en) 2022-10-06
CO2022014044A2 (es) 2022-11-29
WO2021175823A1 (en) 2021-09-10
IL296067A (en) 2022-11-01
JP2023517194A (ja) 2023-04-24
EP4114434A1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
MX2025003080A (es) Conjugados de il-15, y sus usos
MX2023009135A (es) Compuestos de oxazepina tetraciclica y usos de estos.
MX2022010920A (es) Pld para uso en combinación con el tratamiento de coronavirus.
MX2022009164A (es) N4-hidroxicitidina y derivados y usos antivirales relacionados con los mismos.
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
MX2023009527A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos.
GEP20237458B (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
CR20230164A (es) Compuestos fosfolípidos y usos de estos
MXPA04006572A (es) Terapia de combinacion antivirica.
MX2024010591A (es) Compuestos y metodos para el tratamiento de infecciones virales.
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MX2022014034A (es) Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta.
PH12022550118A1 (en) Enzyme inhibitors
MX2025006782A (es) Degradadores de la cinasa 4 asociada al receptor de interleucina-1 (irak4) y usos de los mismos
PH12022551008A1 (en) Anti-cd19 therapy in combination with lenalidomide for the treatment of leukemia or lymphoma
UA83022C2 (uk) Аплідин для комбінованої терапії лейкозу та лімфоми
WO2022053993A3 (en) Treatments for sars-cov-2 infection (covid-19)
MX2023000734A (es) Virus vaccinia recombinante.
MX2022012262A (es) Fitoecdisonas y derivados de estas para su uso en el tratamiento de insuficiencia de la funcion respiratoria durante una infeccion viral.
MXPA05011213A (es) Combinacion de un inhibidor de ciclooxigenasa-2 y un agente antineoplasico tipo alquilacion para tratamiento de neoplasia.
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
WO2022063869A3 (en) Compounds for the treatment of viral infections
MX2020012543A (es) Diltiazem para usarse en el tratamiento de infecciones microbianas.
MX2020010338A (es) Uso de calcifediol en pacientes de cirugia bariatrica.
BRPI0419231A (pt) artigo absorvente compreendendo um cinto